Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Operations: 2021-2025

Historic Cash from Operations for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $39.7 million.

  • Krystal Biotech's Cash from Operations fell 32.62% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.2 million, marking a year-over-year increase of 178.16%. This contributed to the annual value of $123.4 million for FY2024, which is 238.98% up from last year.
  • Latest data reveals that Krystal Biotech reported Cash from Operations of $39.7 million as of Q3 2025, which was down 24.79% from $52.7 million recorded in Q2 2025.
  • Krystal Biotech's Cash from Operations' 5-year high stood at $58.9 million during Q3 2024, with a 5-year trough of -$43.1 million in Q2 2022.
  • Moreover, its 3-year median value for Cash from Operations was $15.9 million (2024), whereas its average is $14.4 million.
  • Per our database at Business Quant, Krystal Biotech's Cash from Operations plummeted by 325.11% in 2022 and then skyrocketed by 1,365.09% in 2025.
  • Over the past 5 years, Krystal Biotech's Cash from Operations (Quarterly) stood at -$20.9 million in 2021, then declined by 6.84% to -$22.3 million in 2022, then soared by 67.61% to -$7.2 million in 2023, then skyrocketed by 830.68% to $52.8 million in 2024, then slumped by 32.62% to $39.7 million in 2025.
  • Its last three reported values are $39.7 million in Q3 2025, $52.7 million for Q2 2025, and $31.0 million during Q1 2025.